# A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

> **NCT07134088** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Amgen** · enrollment: 104 (estimated)

## Conditions studied

- Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
- Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Blinatumomab

## Key facts

- **NCT ID:** NCT07134088
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-12-08
- **Primary completion:** 2028-12-05
- **Final completion:** 2030-06-18
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07134088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07134088, "A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT07134088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*